MedTrace Logo

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

NCT07048886 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2025-07-03

No results posted yet for this study

Summary

The primary objective of this study is to determine if the addition of Rocklatan post-Hydrus will provide additional intraocular pressure lowering.

Conditions

  • Primary Open Angle Glaucoma

Interventions

DRUG

Rocklatan (netarsudil 0.02% and latanoprost 0.005%)

Additional intraocular eye pressure lowering post-Hydrus

DRUG

Systane

Placebo Comparator (artificial tears)

Sponsors & Collaborators

  • Center for Sight Las Vegas

    lead OTHER

Principal Investigators

  • Medical Director, Medical Doctor · Center For Sight

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-15
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07048886 on ClinicalTrials.gov